EU nod for Shire’s longer-acting haemophilia A therapy
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
Read More
Tag: Baxalta
Shire mulls over separation of neuroscience unit
Shire is considering cleaving its neuroscience division into a separate, publicly-listed entity in a move that would afford the firm a sharper focus on rare diseases.
Read More
Baxalta buy drives huge leap in Shire’s Q4 sales
Shire has booked sales of $3.62 billion for the fourth quarter, marking a leap of 123 percent driven by its acquisition of Baxalta last year.
Read More
Shareholders approve $32bn Shire/Baxalta marriage
Shire’s proposal to acquire Baxalta for around $32 billion and create “the global leader in rare diseases” has now been approved by both sets of shareholders.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
